CDKN2B mutation	Triple Negative Breast Cancer	CDKN2B mutation	Triple Negative Breast Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
CDKN2B mutation	Breast Cancer	CDKN2B mutation	Breast Cancer	ribociclib Resistant: B - Late Trials ribociclib Resistant : B	ribociclib Resistant: B - Late Trials ribociclib Resistant : B
IKZF1 deletion + CDKN2B deletion	Acute Myelogenous Leukemia	IKZF1 deletion + CDKN2B deletion	Acute Myelogenous Leukemia	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
CDKN2B mutation	Solid Tumor	CDKN2B mutation	Solid Tumor	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDKN2B mutation	Urothelial Cancer	CDKN2B mutation	Urothelial Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDKN2B deletion	Gastric Adenocarcinoma	CDKN2B deletion	Gastric Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDKN2B deletion	Diffuse Large B Cell Lymphoma	CDKN2B deletion	Diffuse Large B Cell Lymphoma	T-lymphocyte cell therapy Resistant: C3 – Early Trials T-lymphocyte cell therapy Resistant : C3	T-lymphocyte cell therapy Resistant: C3 – Early Trials T-lymphocyte cell therapy Resistant : C3
IKZF1 deletion + CDKN2B deletion	Acute Lymphocytic Leukemia	IKZF1 deletion + CDKN2B deletion	Acute Lymphocytic Leukemia	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3
CDKN2B mutation	Urothelial Cancer	CDKN2B mutation	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3
TMB-H + CDKN2B mutation	Urothelial Cancer	TMB-H + CDKN2B mutation	Urothelial Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
ALK rearrangement + CDKN2B deletion	Non Small Cell Lung Cancer	ALK rearrangement + CDKN2B deletion	Non Small Cell Lung Cancer	ALK inhibitor Resistant: C3 – Early Trials ALK inhibitor Resistant : C3	ALK inhibitor Resistant: C3 – Early Trials ALK inhibitor Resistant : C3
STRN-NTRK2 fusion + CDKN2B Deletion	Soft Tissue Sarcoma	STRN-NTRK2 fusion + CDKN2B Deletion	Soft Tissue Sarcoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4

CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)

Associations(17)

Associations
(17)